High caffeine levels associated with weight loss and type 2 diabetes risk: BMJ

Published Date: 17 Mar 2023

UK: A recent study published in BMJ Medicine found that more caffeine in the blood can reduce the risk of type 2 diabetes and obesity. more...

Read Full News

Latest News

Semaglutide Cuts Calories Even as Appetite Benefits Fade

Adults with overweight or obesity receiving semaglutide eat significantly fewer calories than those on placebo through week 60, despite early gains in appetite control waning after week 20.

Frequent Contraceptive Switching Tied to Semaglutide Use

Those who use hormonal birth control, particularly those who switch methods multiple times, are far more likely to take semaglutide later in life.

Generic Levothyroxine Manufacturer Issues 'Urgent' Recall

The voluntary recall of multiple tablet dosages is for sub-potency.

GLP-1s in IBD: Study Questions Benefits of Newer Drugs

Adjunctive treatment with semaglutide or tirzepatide in patients with inflammatory bowel disease and obesity and/or diabetes may not reduce the risk for disease relapse.

Pregnancy in Trans Men Reveals Major Data Gaps

A new review finds that pregnancy among trans men is real but still poorly studied, leaving clinicians without clear evidence-based guidance.

Obesity Phenotype Predicts Tirzepatide Super Responders

Researchers identify a new subphenotype of obesity marked by fast gastric emptying, low GLP-1 levels, and greater postmeal hunger that is tied to substantially greater weight loss with tirzepatide.

Todays Updates

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Todays Updates

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Latest News

Adults with overweight or obesity receiving semaglutide eat significantly fewer calories than those on placebo through week 60, despite early gains in appetite control waning after week 20.

Those who use hormonal birth control, particularly those who switch methods multiple times, are far more likely to take semaglutide later in life.

The voluntary recall of multiple tablet dosages is for sub-potency.

Adjunctive treatment with semaglutide or tirzepatide in patients with inflammatory bowel disease and obesity and/or diabetes may not reduce the risk for disease relapse.

A new review finds that pregnancy among trans men is real but still poorly studied, leaving clinicians without clear evidence-based guidance.

Researchers identify a new subphenotype of obesity marked by fast gastric emptying, low GLP-1 levels, and greater postmeal hunger that is tied to substantially greater weight loss with tirzepatide.

News All Time

USG Detects Vagus Nerve Atrophy in Parkinson's Disease

Ultrasound imaging reveals structural changes in the vagus nerve of patients with Parkinson's disease in a meta-analysis.

SGLT2-GLP-1 Combo Little Better Than Monotherapy in T2D

Using both SGLT2 inhibitors and GLP-1 receptor agonists is no more effective than using either drug alone in patients with type 2 diabetes, a new meta-analysis suggests.

Mindfulness-Based Eating Improves Anxiety, Eating Behavior

A mindfulness-based eating intervention improved anxiety, depression, and eating behaviors in adults with obesity and generalized anxiety disorder.

5 Common Lab Results: Why Context Matters

Common laboratory tests can mislead when interpreted without clinical context, highlighting why appropriate test selection matters as much as the results themselves.

Lilly Announces More Next-gen Obesity Drug Data, Plans Q1 2027 FDA Application

Eli Lilly said on Thursday that two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit ⁠an application to the...

Efforts Address Immune Suppression in Islet Cell Transplants

Updates suggest progress in the development of less-toxic regimens, and in gene editing to eliminate the need for immune suppression entirely.

Faricimab Reduces Shots, Improves Vision for Retinal Disease

In two studies in retinal disease, faricimab shows improved vision and a reduced injection burden in people who switched from first-generation drugs.

HTTP error: 503

Will Semaglutide Prices Drop After 2026 Patent Expirations?

As patents expire, generic injectable semaglutide could become available at a fraction of current branded prices — around $28-$140 per person-year — in about 162 countries by the end of 2026.

Helping Patients With Diabetes Utilize Technology

Helping patients overcome fear or anxiety around continuous glucose monitoring may be a hurdle.

Novo Sues Lilly, Claiming Misleading Ads in Weight-loss Drug Battle

Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform...

HTTP error: 503HTTP error: 503

Semaglutide Tied to Lower Risk for Adult-Onset Seizure

In adults with type 2 diabetes, semaglutide initiation was associated with roughly half the risk for adult-onset seizure compared with other glucose-lowering medications — a protective effect that appeared independent of blood sugar or weight control.

Alcohol and Marijuana Use in Type 1 Diabetes: What to Know

People with type 1 diabetes are just as likely to use substances as the rest of the population, so they need to be aware of the risks and how to mitigate them.

Glucose, A1c Mediate Obesity-Pancreatic Cancer Link

Higher BMI, waist size, and waist-hip ratio are linked to an increased risk for pancreatic cancer, and part of the association is explained by poor glycaemic control, a study finds.

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world

Featured News

Featured Articles

Featured Events

Featured KOL Videos

1.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

2.

Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma

3.

VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets

4.

New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada

5.

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?

1.

Unlocking the Power of Cryoprecipitate: A Comprehensive Guide

2.

Comprehensive Standards in Oncology for Modern Medicine

3.

Everything You Need to Know About Leiomyomas: A Comprehensive Guide

4.

Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review

5.

Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

4.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

5.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

bot